David Longo is the Co-Founder and Chief Executive Officer (CEO) of Ordaōs. As CEO of Ordaōs, Longo leads a strong scientific team to design novel mini-proteins that help drug hunters deliver safer and more effective treatments.

Longo brings to Ordaōs, broad experience in innovation and technology, that compel him to approach protein design in a unique way. His expertise in AI and machine learning is incorporated into Ordaōs’ Design Engine, driving the rapid creation of never-before-seen mini-proteins with improved probability of more therapeutically effective candidates. Prior to Ordaōs, this entrepreneur led a series of companies which he grew into successful entities.

Longo has an MS in biotechnology from Harvard University, graduate certificates in AI, Machine Learning, Innovation and Technology from Stanford University and Massachusetts Institute of Technology (MIT), and a master’s Certificate in Music Production from Berklee College of Music. He has a Bachelor of Science in Computational Mathematics from Rochester Institute of Technology. David is a learner, triathlete, and an inspirational leader.

Matthias Denecke, PHD, is the Senior Vice President of Engineering at Ordaōs, where he is responsible for the design, implementation and deployment of deep learning technologies for protein generation. Dr. Denecke brings to Ordaōs extensive experience in machine learning, artificial intelligence, and natural language processing. He has advanced expertise in programming and applications as well as identifying, isolating, and resolving technical issues. He is skilled in multiple programming languages and in the ability to build and strengthen relationships across functions to drive cohesive strategic operations. He holds two patents, has several publications, and has conducted a variety of technical projects for major firms including Ford, Deloitte and Pfizer, and research projects for Army Research Lab, ADELPHI, Defense Advanced Research Projects Agency (DARPA) and BOSCH.

Prior to Ordaōs, Dr. Denecke was the Chief Technology Officer for Qeep (qeep.ai) where he built interactive technical documentation with AI-supported conversational interfaces to help engineers work more productively and reduce human errors. Before that, Dr. Denecke was the Co-Founder of Agilingua where he developed interactive spoken language applications based on their proprietary ATOM Dialogue Engine which was used in in-car infotainment systems, interactive electronic manuals, human-robot interactions, and computer-assisted language learning.

Dr. Denecke received his PHD in Rapid Prototyping of Spoken Dialogue Systems from the University of Karlsruhe. He earned a diploma in Computational Linguistics from the University of Stuttgart and a diploma in Computer Science at the University of Karlsruhe.

Dr. Victor Bustos is the Vice President of Preclinical R&D at Ordaōs, where he leads the company’s wet-lab efforts. He oversees multidisciplinary teams responsible for rapid protein expression, purification, and functional characterization of novel protein binders, including nanobodies and miniproteins, that emerge from Ordaōs’s generative models.

Dr. Bustos brings over twenty years of experience in neuroscience, protein engineering, and translational research, with a particular focus on neurodegenerative diseases. He has deep expertise building laboratories from the ground up, implementing cell-free protein expression platforms, and operationalizing lab-in-the-loop workflows that support machine-learning–guided biologics discovery. Over his career he has authored more than thirty peer-reviewed publications, led cross-functional research programs, and mentored teams at the interface of biology, data, and technology.

Prior to joining Ordaōs, Dr. Bustos spent thirteen years in the laboratory of Nobel Laureate Paul Greengard at The Rockefeller University, where he led projects in molecular and cellular neuroscience relevant to neurodegenerative disorders. He later played a key role in the Drug Discovery Resource Center, supporting high-throughput and biophysical approaches, including SPR, MST, and complex cell-based assays for target validation and mechanism-of-action studies.

Dr. Bustos earned his PhD in Biochemistry from the University of Chile, where he trained under Dr. Jorge Allende, a pioneer in cell-free expression. His early work in cell-free translation systems laid the foundation for the rapid protein prototyping workflows he later helped implement at Ordaōs, enabling fast, iterative design–build–test cycles for next-generation biologics.